Bioverativ
ID: 5082908Bioverativ is a global biotechnology company developing therapies for hemophilia and other rare blood disorders, including sickle cell disease and beta-thalassemia.
Overview
Bioverativ is a global biotechnology company developing therapies for hemophilia and other rare blood disorders, including sickle cell disease and beta-thalassemia.
- Websites:
- Business model: B2B
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Industries
Bioverativ is active in the following industries: